Amgen Inc.
AMGN Healthcare Drug Manufacturers General
Amgen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36.8 billion, up 9.95% from fiscal 2024. In the quarter to June 2026, revenue grew 9.53%, EPS grew 65.4%, free cash flow grew 82.6% and total debt rose 1.96%, each against the same quarter a year earlier. Member of the S&P 500, Nasdaq 100 and Dow Jones; dividend growth for ten consecutive years, revenue growth for five.
Follow AMGN
Amgen Inc. (AMGN) Return on equity
Amgen Inc.'s return on equity over the twelve months to 30 June 2026 was 91.5%, down 14.6 percentage points from fiscal 2025 (106.1%). Over the past ten years it has ranged from 7.18% (fiscal 2017) to 135.8% (fiscal 2023); the current reading is higher than 82% of that period. That is above the Drug Manufacturers General industry median of 5.87% and above the Healthcare sector median of −31.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 106.1% | 38.55 |
| FY2024 | 67.6% | (68.24) |
| FY2023 | 135.8% | 9.32 |
| FY2022 | 126.5% | 53.31 |
| FY2021 | 73.2% | (2.97) |
| FY2020 | 76.1% | 5.40 |
| FY2019 | 70.7% | 26.25 |
| FY2018 | 44.5% | 37.30 |
| FY2017 | 7.18% | (19.47) |
| FY2016 | 26.7% | 0.88 |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| AMGN Amgen Inc. | 91.5% |
| NVO Novo Nordisk A/S compare | 60.8% |
| BMY Bristol Myers Squibb Company compare | 46.6% |
| NVS Novartis AG compare | 30.4% |
| AZN AstraZeneca PLC compare | 22.0% |
| MRK Merck & Co., Inc. compare | 6.97% |
| PFE Pfizer Inc. compare | 4.97% |
| GILD Gilead Sciences, Inc. compare | −20.7% |
| ABBV AbbVie Inc. compare | −208.1% |
| Drug Manufacturers General industry median | 5.87% |
| Healthcare sector median | −31.3% |
| Market median | 1.35% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on AMGN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement